Current Approaches Against Alzheimer's Disease in Clinical Trials

Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a dru...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Brazilian Chemical Society Vol. 27; no. 4; pp. 641 - 649
Main Authors Kuca, Kamil, Soukup, Ondrej, Maresova, Petra, Korabecny, Jan, Nepovimova, Eugenie, Klimova, Blanka, Honegr, Jan, Ramalho, Teodorico C., França, Tanos C. C.
Format Journal Article
LanguageEnglish
Published Sociedade Brasileira de Química 01.04.2016
Subjects
CHEMISTRY, MULTIDISCIPLINARY
treatment
rivastigmine
epigallocatechin gallate
tacrine
huperzine A
encenicline
valproic acid
galantamine
atorvastatin
etazolate
tramiprosate
methylene blue
ABT-126
pioglitazone
semagacestat
thalidomide
minocycline
immunotherapy
donepezil
rosiglitazone
AC-42
arecoline
Alzheimer's disease
tideglusib
Online AccessGet full text

Cover

More Information
Summary:Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.
ISSN:0103-5053
1678-4790
DOI:10.5935/0103-5053.20160048